Clinical Trial: A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Brief Summary: The purpose of this study is to evaluate the safety of FCX-007, evaluate C7 expression and the presence of anchoring fibrils resulting from FCX-007 and to analyze wound healing as a result of FCX-007 administration in subjects with RDEB.